Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07527156

Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure

Feasibility and Safety of Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
Institute for Clinical and Experimental Medicine · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the feasibility and safety of achieving therapeutic concentrations of beta-hydroxybutyrate using continuous infusion of D-beta-hydroxybutyrate monoester administered via a nasogastric tube in patients with acutely decompensated heart failure with reduced left ventricular ejection fraction.

Detailed description

Adult patients with left ventricular ejection fraction (LVEF) \<35% admitted to the intensive care unit for acutely decompensated heart failure with low cardiac output syndrome or cardiogenic shock will receive a continuous infusion of D-3-hydroxybutyrate (3-OHB) monoester via a nasogastric tube for 36 hours. The infusion rate will be iteratively adjusted to achieve an arterial blood concentration of 3-OHB of 2-3.5 mmol/L. Arterial blood concentrations of 3-OHB will be measured every 1-3 hours using point-of-care testing. The primary endpoint will be the proportion of time within the target concentration range. Secondary safety endpoints will include worsening of liver function not attributable to hemodynamic deterioration, occurrence of cardiac arrhythmias, and gastrointestinal tolerance of the infusion.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTKetone Monoester (KE)Continous infusion of a commercially available ketone monoester via nasogastric tube.

Timeline

Start date
2026-04-04
Primary completion
2027-03-31
Completion
2027-03-31
First posted
2026-04-14
Last updated
2026-04-14

Locations

1 site across 1 country: Czechia

Source: ClinicalTrials.gov record NCT07527156. Inclusion in this directory is not an endorsement.